Trials / Sponsors / Uma Borate
Uma Borate
Academic / Other · 7 registered clinical trials — 4 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Elig Acute Myeloid Leukemia | Phase 2 | 2026-04-10 |
| Recruiting | Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Ne Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 / Phase 2 | 2024-08-02 |
| Recruiting | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation | Phase 1 | 2024-02-20 |
| Recruiting | Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Signific Clonal Cytopenia of Undetermined Significance | Phase 2 | 2023-02-06 |
| Active Not Recruiting | Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome | Phase 2 | 2022-06-23 |
| Completed | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia | EARLY_Phase 1 | 2020-11-05 |
| Completed | Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Nov Acute Myeloid Leukemia | Phase 1 | 2019-03-13 |